The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation.
BACKGROUND
Treatment of hookworm-related cutaneous larva migrans (HrCLM) with a single dose of oral ivermectin has not been adequately evaluated to date. Response rates reported in three large studies varied from 77% to more than 95%.


OBJECTIVE
We evaluated the efficacy of ivermectin in the treatment of HrCLM.


METHODS
We retrospectively studied all returning travellers with HrCLM who consulted in our institution. Patients were then treated with a single, 200 μg/kg dose of ivermectin, orally.


RESULTS
Sixty-two travellers (35 female, 27 male, mean age 35.6 years) with HrCLM and creeping dermatitis were included. Six patients (10%) also had associated hookworm folliculitis. Fifty-nine patients (95%) completely responded with one ivermectin dose. The response rate was 98% in the 56 patients presenting with only creeping dermatitis and 66% in the six patients presenting with additional hookworm folliculitis (P = 0.02).


CONCLUSIONS
The efficacy of a single dose of oral ivermectin is higher in patients with only creeping dermatitis than in those with associated hookworm folliculitis.
Service de Maladies Infectieuses et Tropicales, Hôpital Pitié Salpêtrière, Paris, France.
C
C
Vanhaecke
A
A
Perignon
G
G
Monsel
S
S
Regnier
F
F
Bricaire
E
E
Caumes
D000293:Adolescent; D000328:Adult; D000368:Aged; D000871:Anthelmintics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006725:Hookworm Infections / Q000188:drug therapy*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012876:Skin Diseases, Parasitic / Q000188:drug therapy*; D055815:Young Adult
D000871:Anthelmintics; D007559:Ivermectin